Research ArticleClinical Investigations
Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
Anne Roivainen, Esa Kähkönen, Pauliina Luoto, Sandra Borkowski, Birte Hofmann, Ivan Jambor, Kaisa Lehtiö, Tuija Rantala, Antje Rottmann, Henri Sipilä, Rick Sparks, Sami Suilamo, Tuula Tolvanen, Ray Valencia and Heikki Minn
Journal of Nuclear Medicine June 2013, 54 (6) 867-872; DOI: https://doi.org/10.2967/jnumed.112.114082
Anne Roivainen
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
Esa Kähkönen
2Department of Urology, Turku University Hospital, Turku, Finland
Pauliina Luoto
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
Sandra Borkowski
3Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Berlin, Germany
Birte Hofmann
3Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Berlin, Germany
Ivan Jambor
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
Kaisa Lehtiö
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
4Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; and
Tuija Rantala
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
Antje Rottmann
3Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Berlin, Germany
Henri Sipilä
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
Rick Sparks
5CDE Dosimetry Services, Inc., Knoxville, Tennessee
Sami Suilamo
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
4Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; and
Tuula Tolvanen
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
Ray Valencia
3Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Berlin, Germany
Heikki Minn
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
4Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; and

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 54, Issue 6
June 1, 2013
Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
Anne Roivainen, Esa Kähkönen, Pauliina Luoto, Sandra Borkowski, Birte Hofmann, Ivan Jambor, Kaisa Lehtiö, Tuija Rantala, Antje Rottmann, Henri Sipilä, Rick Sparks, Sami Suilamo, Tuula Tolvanen, Ray Valencia, Heikki Minn
Journal of Nuclear Medicine Jun 2013, 54 (6) 867-872; DOI: 10.2967/jnumed.112.114082
Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
Anne Roivainen, Esa Kähkönen, Pauliina Luoto, Sandra Borkowski, Birte Hofmann, Ivan Jambor, Kaisa Lehtiö, Tuija Rantala, Antje Rottmann, Henri Sipilä, Rick Sparks, Sami Suilamo, Tuula Tolvanen, Ray Valencia, Heikki Minn
Journal of Nuclear Medicine Jun 2013, 54 (6) 867-872; DOI: 10.2967/jnumed.112.114082
Jump to section
Related Articles
Cited By...
- A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry
- Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease
- First-in-Human Serum Stability Studies of [177Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy
- Preclinical Comparison of the 64Cu- and 68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga]Ga-AMTG PET/CT
- Substitution of L-Tryptophan by {alpha}-Methyl-L-Tryptophan in 177Lu-RM2 Results in 177Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability
- GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naive Patients
- MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
- Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
- Radiosynthesis and Preclinical Evaluation of [68Ga]Ga-NOTA-Folate for PET Imaging of Folate Receptor {beta} Positive Macrophages
- Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
- Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging
- Will GRPR Compete with PSMA as a Target in Prostate Cancer?
- Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist
- Bombesin-Targeted PET of Prostate Cancer
- Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer
- 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients
- Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB
- Preclinical Comparison of Al18F- and 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer
- N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of 68Ga- and 64Cu-Labeled Peptides for PET Imaging
- A High-Affinity, High-Stability Photoacoustic Agent for Imaging Gastrin-Releasing Peptide Receptor in Prostate Cancer
- In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548